Compare FINV & ENOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FINV | ENOV |
|---|---|---|
| Founded | 2007 | 1995 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Fluid Controls |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | N/A | 2008 |
| Metric | FINV | ENOV |
|---|---|---|
| Price | $5.04 | $30.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $11.55 | ★ $51.17 |
| AVG Volume (30 Days) | ★ 1.7M | 899.4K |
| Earning Date | 11-19-2025 | 11-06-2025 |
| Dividend Yield | ★ 5.72% | N/A |
| EPS Growth | ★ 27.76 | N/A |
| EPS | ★ 1.50 | N/A |
| Revenue | $1,969,555,571.00 | ★ $2,233,266,000.00 |
| Revenue This Year | $11.56 | $9.13 |
| Revenue Next Year | $8.06 | $6.39 |
| P/E Ratio | $3.33 | ★ N/A |
| Revenue Growth | 8.81 | ★ 11.57 |
| 52 Week Low | $4.70 | $25.47 |
| 52 Week High | $11.08 | $49.75 |
| Indicator | FINV | ENOV |
|---|---|---|
| Relative Strength Index (RSI) | 33.21 | 51.35 |
| Support Level | $4.70 | $26.69 |
| Resistance Level | $5.29 | $30.85 |
| Average True Range (ATR) | 0.25 | 1.30 |
| MACD | -0.04 | 0.16 |
| Stochastic Oscillator | 19.82 | 63.55 |
FinVolution Group is a provider of online consumer finance in China. The company offers various loan products, making financial services available to borrowers anytime, anywhere; designs a loan transaction process, and offers tailored risk-based pricing. It offers short-term loans to borrowers to meet immediate credit needs while allowing them to gradually establish their credit history through activities on the company's platform. The company generates revenues from fees charged to borrowers. The Group's long-lived assets are located in the PRC, and its revenues are derived from within the PRC.
Enovis Corp is a medical technology company that offers medical devices and services across the continuum of patient care, from injury prevention to joint replacement to rehabilitation after surgery, injury, or degenerative disease. Its reportable segments are Prevention & Recovery (P&R) and Reconstructive (Recon). The company generates the maximum revenue from the Prevention & Recovery segment, which includes products that are used to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports-related injuries. The Reconstructive segment provides a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and surgical productivity tools. Geographically, it derives key revenue from the U.S.